Surgical issues in the management of melanoma

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 183-188

  Fraker, Douglas L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MELPHALAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; SKIN CANCER; SURVIVAL TIME;

EID: 0030913047     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00014     Document Type: Review

References (40)

1. Goldman LI: The surgical therapy of malignant melanomas. Semin Oncol 1975, 2:175-178.
2. Handley WS: The pathology of melanotic growths in relation to their operative treatment Lancet 1907, 1:927-933, 996-1003.
3. Breslow A, Macht SD: Optimal size of resection margins for thin cutaneous melanoma. Surg Gynecol Obstet 1977, 145:691-692.
4. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, Bufalino R, Craig P, De Marsillac J, Durand JC, et al.: Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988, 318:1159-1162.
5. Balch CM, Milton GW, Cascinelli N, Sim FH: Elective lymph node dissection: pros and cons. In Cutaneous Melanoma, 2nd edn, Edited by Balch CM, Houghton A, Milton GW, et al. Philadelphia: JB Lippincott; 1992:345-366.
6. McCarthy WH, Shaw HM, Cascinelli N, Santinami M, Belli F: Elective lymph node dissection for melanoma: two perspectives. World J Surg 1992, 16:203-213.
7. Balch C: The role of elective lymph node dissection in melanoma: rationale, results and controversies. J Clin Oncol 1988, 6(suppl 1):163-172.
8. Karakousis CP, Emrich LJ, Driscoll DL, Rao U: Survival after groin dissetion for malignant melanoma. Surgery 1991, 109:119-126.
9. Coit DG, Brennan MF: Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989,124:162-166.
10. Finck SJ, Giuliann AE, Mann BD, et al.: Results of ileoinguinal dissection for stage II melanoma. Ann Surg 1982, 196:180-186.
11. Balch CM: Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer. Surgery 1990, 108(suppl 1):118-119.
12. Warso MA, Das Gupta TK: Melanoma recurrence in a previously dissected lymph node basin. Arch Surg 1994, 129:252-255.
13. Barth RJ, Venzon DJ, Baker AR: The prognosis of melanoma patients with metastases to two or more lymph node areas. Ann Surg 1991, 214:125-130.
14. Morton DL, Wanek L, Nizze A, Elashoff RM, Wong JH: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 1991, 214:491-501.
15. Coit DG, Rogatko A, Brennan MF: Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. Ann Surg 1991, 214:627-636.
16. Veronesi U, Adamus J, Bandiera BC, Brennhovd IO, Caceres E, Cascinalli N, Claudio F, Ikonopisov RL, Javorskj VV, Kirov S, et al.: Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977, 297:627-630.
17. Sim FH, Taylor WF, Pritchard DJ, Soule EH: Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986, 61:697-705.
18. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanoma for patients 60 years of age or younger. Ann Surg 1996, 224:255-266. The initial report of the most recent and largest prospective randomized trial looking at elective lymph node dissection. Subset analysis defines certain groups with survival benefit.
19. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, Schroer K, Heller R, Ross M, Lyman G, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759-767.
20. Morton DL, Wen DR, Cochran AJ: Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy: an alternative to routine elective lymphadenectomy or "Watch and Wait". Surg Oncol Clin N Am 1992, 1:247-259.
21. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, Laughlin EH, Alex JC: Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995, 130:654-660. Recent report of an experienced investigation in the technique and results of lymph node mapping for melanoma.
22. Morton DL, Wen DR, Wong JH, Economou JS, Casgle LA, Storm FK, Foshag LJ, Cochran AJ: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
23. Heller R, Becker J, Wasselle J, Baekey P, Cruse W, Wells K, Cox C, King B, Reintgen DS: Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg 1991, 126:1455-1460.
24. Wang X, Heller R, Van Voorhis N, Cruse CW, Glass F, Fenske N, Berman C, Leo-Messina J, Rappaport D, Wells K, et al: Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994, 220:768-774.
25. Kirwood JM, Strawderman MH, Ernstoff MS, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996, 14:7-17.
26. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994, 271:907-914.
27. Wornom IL III, Soong SJ, Urist MM, Smith JW, McElvein R, Balch CM: Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986, 204:181-185.
28. Pogrebniak HW, Stovroff M, Roth JA, Pass HI: Resection of pulmonary metastases from malignant melanoma: results of a 16-year experience. Ann Thorac Surg 1988, 46:20-23.
29. Karp NS, Boyd A, DePan HJ, Harris MN, Roses DF: Thoracotomy for metastatic malignant melanoma of the lung. Surgery 1990, 107:256-261.
30. Thayer JO, Overholt RH: Metastatic melanoma to the lung: long-term results of surgical excision. Am J Surg 1985, 149:556-562.
31. Wong JH, Euhus DM, Morton DL: Surgical resection for metastatic melanoma to the lung. Arch Surg 1988, 123:1091-1095.
32. Branum GD, Epstein RE, Leight GS, Seigler HF: The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery 1991, 109:127-131.
33. Klaase JM, Kroon BBR: Surgery for melanoma metastatic to the gastrointestinal tact. Br J Surg 1990, 77:60-61.
34. Reintgen DS, Thompson W, Garbutt J, Seigler HF: Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery 1984, 95:635-640.
35. Ihde JK, Coit DG: Melanoma metastatic to stomach, small bowel, or colon. Am J Surg 1991, 162:208-211.
36. Koops HS, Kroon BBR, Lejeune FG: Isolated regional perfusion in the treatment of local recurrence, satellites and in-transit metastases of extremity melanomas. In Therapy of Advanced Melanoma. Edited by Rumke P. Basel: Pigment Cell; 1990:67-78.
37. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994, 115:39-45.
38. Fraker DL, Alexander HR: Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In Important Advances in Oncology 1994. Edited by DeVita VT, Hellman S, Rosenberg SA. JB Lippincott Co: Philadelphia, 1994:179-192.
39. Lienard D, Lejeune FJ, Ewalenko P: In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion. World J Surg 1992, 16:234-240.
40. Fraker DL, Alexander HR, Andrich M, Rosenberg SA: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and Interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996, 14:479-489. The results of addition of high-dose tumor necrosis factor to melphalon for isolated limb perfusion of regional extremity melanoma. This report summarizes the United States experience.